365-29-7

Basic information

• Product Name: N-(2,3,4-trifluorophenyl)acetaMide
• Synonyms: N-(2,3,4-trifluorophenyl)acetaMide;2',3',4'-Trifluoroacetanilide
• CAS NO: 365-29-7
• Molecular Formula: C₈H₆F₃NO
• Molecular Weight: 189.1345496
• Mol File: 365-29-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(2,3,4-trifluorophenyl)acetaMide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2,3,4-trifluorophenyl)acetaMide(365-29-7)
• EPA Substance Registry System: N-(2,3,4-trifluorophenyl)acetaMide(365-29-7)

Safety Data

• Hazardous Substances Data: 365-29-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-(2,3,4-trifluorophenyl)acetamide is used as a building block for the synthesis of various pharmaceuticals. Its strong electron-withdrawing properties contribute to the development of new drugs with improved efficacy and safety profiles.
Used in Agrochemical Industry:
In the agrochemical industry, N-(2,3,4-trifluorophenyl)acetamide serves as a key component in the synthesis of novel agrochemicals. Its unique properties enable the creation of more effective and environmentally friendly pesticides and herbicides.
Used in Organic Electronics:
N-(2,3,4-trifluorophenyl)acetamide is utilized as a building block in the development of new materials for organic electronics. Its electron-withdrawing properties make it suitable for applications in organic light-emitting diodes (OLEDs), organic solar cells, and other electronic devices, enhancing their performance and stability.
Used in Chemical Reactions:
Due to its strong electron-withdrawing properties, N-(2,3,4-trifluorophenyl)acetamide is employed in a wide range of chemical reactions. It can act as a catalyst or intermediate, facilitating the synthesis of various organic compounds and improving the overall efficiency of the reaction process.

Upstream product

• 3862-73-5 2,3,4-trifluoroaniline 
• 108-24-7 acetic anhydride 

Downstream Products

• 148416-38-0 6-nitro-2,3,4-trifluoroaniline 
• 587847-30-1 4,5,6-trifluoro-2-nitrophenylazide 
• 168966-54-9 3,4,5-Trifluoro-1,2-phenylenediamine 
• 290313-50-7 6-nitro-2,3,4-trifluoroacetanilide 

Relevant articles and documents

A PROCESS FOR THE PREPARATION OF 3,4,5-TRIFLUORONITROBENZENE

The present invention relates to a process for the preparation of 3,4,5-trifluoronitrobenzene of the formula (1). The process involved straightforward transformations and eventually culminated in consistent preparation of the title compound in good quantities.

Synthesis of novel fluorobenzofuroxans by oxidation of anilines and thermal cyclization of arylazides

The synthesis of several fluorobenzofuroxans by oxidation of fluoroanilines and thermal cyclization of fluoroarylazides is presented. The fluorobenzofuroxans prepared in this study presented tautomerism as evidenced by their NMR data. Benzofuroxans in general have biological activity and are synthetic intermediates for the preparation of several compounds with important pharmaceutical applications.

Glycine receptor antagonists and the use thereof

Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating psychosis are disclosed by administering to an animal in need of such treatment a compound having high affinity for the glycine binding site, lacking PCP side effects and which crosses the blood brain barrier of the animal. Also disclosed are novel 1,4-dihydroquinoxaline-2,3-diones, and pharmaceutical compositions thereof. Also disclosed are highly soluble ammonium salts of 1,4-dihydroquinoxaline-2,3-diones.

Synthesis and structure-activity relationships of substituted 1,4- dihydroquinoxaline-2,3-diones: Antagonists of N-methyl-D-aspartate (NMDA) receptor glycine sites and non-NMDA glutamate receptors

A series of mono-, di-, tri-, and tetrasubstituted 1,4- dihydroquinoxaline-2,3-diones (QXs) were synthesized and evaluated as antagonists at N-methyl-D-aspartate (NMDA)/glycine sites and α-amino-3- hydroxy-5-methylisoxazole-4-propionic acid-preferring non-NMDA receptors. Antagonist potencies were measured by electrical assays in Xenopus oocytes expressing rat whole brain poly(A)+ RNA. Trisubstituted QXs 17a (ACEA 1021), 17b (ACEA 1031), 24a, and 27, containing a nitro group in the 5 position and halogen in the 6 and 7 positions, displayed high potency (K(b) ~ 6-8 nM) at the glycine site, moderate potency at non-NMDA receptors (K(b) = 0.9-1.5 μM), and the highest (120-250-fold) selectivity in favor of glycine site antagonism over non-NMDA receptors. Tetrasubstituted QXs 17d,e were more than 100-fold weaker glycine site antagonists than the corresponding trisubstituted QXs with F being better tolerated than Cl as a substituent at the 8 position. Di- and monosubstituted QXs showed progressively weaker antagonism compared to trisubstituted analogues. For example, removal of the 5-nitro group of 17a results in a ~100-fold decrease in potency (10a,b,z), while removal of both halogens from 17a results in a ~3000-fold decrease in potency (10v). In terms of steady-state inhibition, most QX substitution patterns favor antagonism at NMDA/glycine sites over antagonism at non-NMDA receptors. Among the QXs tested, only 17i was slightly selective for non- NMDA receptors.